MDxHealth SA (MDXH) - Financial and Strategic SWOT Analysis Review

MDxHealth SA (MDXH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The companys products portfolio includes ConfirmMDx, which detects absence or presence of prostate cancer; SelectMDx for prostate cancer; and AssureMDx for bladder cancer. Its pipeline products include InformMDx, and MonitorMDx which is being developed for Prostate Cancer Test. MdxHealth tests are based on MSP (Methylation-Specific polymerase chain reaction) technology, a proprietary DNA-based platform. It also offers biomarker development services to many pharmaceutical companies. MDxHealth markets its products through sales forces, partnerships and distributors. The company has operations in, the Netherlands, Belgium and the US. MDxHealth is headquartered in Herstal, Liege, Belgium.

MDxHealth SA Key Recent Developments

Aug 29,2019: MDxHealth reports half year 2019 financial results and strategic update
Apr 24,2019: MDxHealth provides Q1 2019 business update
Feb 28,2019: MDxHealth reports financial year 2018 results and provides outlook for 2019
Feb 19,2019: MDxHealth names Michael K. McGarrity as CEO
Jan 14,2019: MDxHealth provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses.